NuggMD, the nation’s leading cannabis market for telemedicine provided free online medical marijuana tests to Oklahoma’s veterans on Monday, 11th Nov. This service was accessible by showing a valid ID as a proof of service.
The Chief Marketing Officer and Co-Founder of NuggMD Alex Milligan said “None of us would enjoy the freedom and prosperity that we do today without our brave veterans. We are offering completely free medical marijuana evaluations to Oklahoma’s veterans this Monday in humble thanks for their service and sacrifice.”
Since the launch in 2016, NuggMD’s affiliated physicians have provided medical marijuana evaluations to nearly half a million patients in California, Nevada and New York. NuggMD officially launched in Oklahoma in 2019 and they are soon planning to expand nationwide.
Co-Founder Kam Babazade said: “The past seven weeks in Oklahoma have been amazing, response to our telemedicine services have far exceeded our expectations, and we’re very excited to see what 2020 will bring for the Midwest.”
Patients can complete the evaluation process with their new physician from home by using NuggMD’s video-enabled telemedicine platform. The evaluations are made easy for disabled or patients who are unable to travel by providing live chat feature. The evaluation can be done through the patient’s smartphone or computer.
NuggMD is the country’s top medical cannabis technology programme. They encourage access to doctors who give medicinal cannabis assessments in California, New York, Nevada and Oklahoma. NuggMD’s patients get their cannabis assessments totally online from the protection and solace of their own home. Since 2016, NuggMD has helped about a large portion of a million medical cannabis patients with the assessment procedure, advancing their main goal to improve personal satisfaction through cannabis.
FDA Approves Trials to Test the Effectiveness of Anti-Malarial Drugs Against COVID-19
As touted by President Donald Trump, on Sunday, an emergency authorization was issued by the Food and Drug Administration (FDA) in Washington. It was regarding the use of chloroquine and hydroxychloroquine – both anti-malaria drugs, for experimental coronavirus treatments, despite the inconclusive clinical proof of their efficacy.
However, on Sunday, the Department of Health and Human Services had announced that distribution of hydroxychloroquine and chloroquine products can be done by doctors, and they may prescribe these drugs to hospitalized teen and adult patients that are infected with COVID-19, as appropriate, in the situation where the availability or feasibility of a clinical trial are not seen.
According to HHS, 30 million doses of hydroxychloroquine has already been given by Germany’s Sandoz, to the Strategic National Stockpile – the inventory of medical supplies for public health emergencies, of the Federal Government. Meanwhile, Bayer has reported having donated a million doses of chloroquine, according to the international media.
HSS further added that the issuance of the emergency authorization was due to the potential benefits of the product that seemed to outweigh the risks. HHS further acknowledged that some benefit in the treatment of hospitalized COVID-19 patients may be offered by these drugs, as suggested by the anecdotal reports. However, HSS cautioned the need for clinical trials, so that the effectiveness of these treatments can be backed up with scientific evidence.
Amidst the ambiguity, some Americans have attempted to seek over-the-counter replacements. An example was the man from Arizona who had bought a nonpharmaceutical form of chloroquine phosphate – a common chemical used for the cleanliness of fish tanks, which ultimately killed him, landing his now-widow in intensive care.
Consumption of non-pharmaceutical chloroquine phosphate without a prescription and supervision of a certified health care provider is warned by the CDC due to the dangers of it causing serious health consequences, including death.
While President Donald Trump continues his support and praise for anti-malarial drugs in daily press briefings, Fox news has released separate segments specifically devoted to the drugs’ potential benefits. Chloroquine and hydroxychloroquine as coronavirus cures have been further promoted by others, including the President’s personal lawyer Rudy Guiliana, and Turning Points USA founder Charlie Kirk.
Furthermore, a tweet by Giuliani was removed by Twitter, since Giuliani had falsely claimed hydroxychloroquine to have a 100% effective treatment rate for COVID-19, despite no scientific proof.
However, scientists hope the decade-old drugs – chloroquine and hydroxychloroquine, may show effectiveness as a treatment for COVID-19, despite early studies providing mixed evidence regarding their effectiveness, due to the potential associated risks such as vision problems or cardiac arrest.
Prescription limiting rules have been issued by some state pharmacy boards including Texas, Louisiana, Ohio, and North Carolina.
A nationwide trial is underway to test the effectiveness of the drug hydroxychloroquine as a vaccine for COVID-19, while a second trial will test the effectiveness of the drug in the treatment of COVID-19.
David Boulware, an infectious disease scientist at the University of Minnesota, is currently running trials. According to Boulware, the rationale for trying it as a vaccine for COVID-19 is based on laboratory studies that would have shown the capability of the drug of keeping COVID-19 from entering cells. Boulware and his team are currently looking for people that have recently been in contact with a COVID-19 infected case, such as health workers or people living with an infected person, and are recruiting online.
To avoid the placebo effect, the trial will be double-blind. Furthermore, Boulware says the trial is approved by the FDA.
An initial look at the results will be taken next week by a committee of independent experts known as the data safety and monitoring board.
A Novel Way to Diagnose an Early Stage Cancer
Typically, cancer is difficult to diagnose at the initial stage. This early-stage diagnosis reduces its complications and the mortality rate linked with it. In many countries, cancer is usually diagnosed in later stages which affects the quality of life and results in greater morbidity rates and high treatment costs. Addressing the delays in the detection of cancer and the unavailability of effective treatment is therefore critical in all the health care settings for cancer control.
Early diagnosis strategies are used to confirm the presence of disease, monitor the process of disease and plan interventions to prevent the disease from progression. These strategies help to improve the cancer outcomes by providing care and effective treatments at the initial stage.
Factors that hinder the cancer diagnosis must be identified and addressed so that it becomes easy to implement effective treatment programs at various levels including improving diagnostic and referral capacity, community engagement to address the behavior of the patient, and ensuring the timely access to high-quality treatment.
A team of researchers led by Professor Jenny Yang from the Georgia State University Regents identified a new method for detecting cancer at the initial stage. This method used the target MRI contrast agent that binds with proteins and detects cancer. The study is published in journal Science Advances.
To detect the metastases of the liver, new biomarkers have been identified by Yang and her colleagues at Georgia State and Emory University. Currently, cancer is diagnosed in its late stages such as biopsies. At this stage treatment options become limited and it ultimately lowers the survival rates. The recent discovery discussed in this study provides a wide range of options that includes precise treatments, effective diagnosis and reduce risk for patients.
Yang said that this method is effective as it will have many applications for diagnosis and treatment of any type of cancer. This method is already used in the lab for 10 different types of cancer.
National Cancer Institute-funded this researcher project. Researchers developed an agent which can target specific receptors known as Chemokine receptor 4 (CXCR4). In the cancerous cells, this receptor is expressed more than normal in metastasis organs such as the liver.
It would be expected that small instances of cancer can be diagnosed through CXCR4 targeted protein-based MRI contrast agent because it beats all the barriers that hinder the early diagnosis of cancer. This new methodology shows the cancerous cells on multi-color scans known as precision MRI (pMRI).
In MRI technology, Gadolinium is used in contrast to agents that enhance the quality of images. In her previous research analyzing calcium, Yang decided to check the interaction of the metal with proteins. She found that the element wraps the protein around itself and takes it to the site where the image is being formed.
Still is it difficult to diagnose cancer in the early stages even though invasive biopsies. The diagnostic tests that use these contrast agents not only detect the presence of cancerous cells but can distinguish the diseases into different stages. The beauty of this test lies in its high accuracy and sensitivity.
The U.S. Food and Drug Administration used the targeted protein contrast agent in the first step of clinical trials to check its efficiency in humans. Yang hopes that these clinical trials in patients will be conducted within 18 months to two years.
Yang is an associate professor at the Center for Diagnosis and Therapeutics. She enrolled 18 foreign and 17 U.S patients in protein engineering. Recently, the National Academy of Inventors awarded her a fellowship. Also, she has started a new company ‘InLight Biosciences’ that allows her to compete for new findings and introduced her latest discoveries to the world.
This research is based on the 2019 study published in the journal Nature Communications. In this study yang and her team identified liver fibrosis for the first time by using a collagen targeted protein contrast agent.
Yang further added that this contrast agent is used for more than 30 years in different aspects and it is my biggest contribution to the scientific world and hoping for the more to come in the future.
New Technology to Predict Cancer Recurrence in Melanoma Patients
The beginning of melanoma takes place when a small pigmented spot appears on the skin. By removing the lesion, a primary melanoma can be treated but it has a tendency of reoccurrence and can spread throughout the body. A new study showed that the likelihood of cancer can be predicted after the removal of the lesion.
Despite all medical advancements, the analysis of lesion his performed in the same old way. Generally, molecular diagnostic labs have many advances for the detection of other forms of cancer but for the skin lesion cancer the way of diagnosis is very simple. The diagnosis is based on the thickness of the melanoma and microscopic features.
A patient with thinner melanomas is considered to be normal and the T stage from 1 to 4 is assigned. The complete details of this study are published in Nature Cancer.
The researchers from the Brigham and Women’s Hospital in collaboration with international colleagues showed a new technique about the reoccurrence and spread of melanomas. It leverages the sequences of DNA for predicting the possible factors involved in the reoccurrence and spread of melanomas.
Thomas Kupper who is the chairperson of the department of dermatology at the Brigham that there were no treatments available for metastatic melanoma 10 years ago. But now it is possible to treat the patients who have metastatic melanoma and these treatments can be given at the primary stage of the disease. It is important to have a clear idea about the patient’s progress report after giving the new immunotherapy treatments, so we can modify the treatment.
There are immune checkpoint inhibitors that can reinitiate the immune response through T cell against the cancer cells. These inhibitors have changed the results and options for the patients in which cancer has spread throughout the body. Immune checkpoint inhibitors can start dramatic responses such as long-term remission in the period of curing a patient.
Kupper and colleagues wanted to know about some measurable features of T cells. These features are used to check the predictions of the reoccurrence of melanoma in the removed primary melanoma and disease-free patients. Scientists study T2, T2, and T4 primary melanoma as the T1 are rarely metastasized melanoma.
They also face difficulty in finding the sample that was enough for results because skin lesion surgeries are usually performed at private clinics and ambulatory clinics. So, the concentration of the specimen is not available in the hospitals. For resolving this issue and for sharing the resources researchers collaborated with colleagues of the Melanoma Institute of Australia and the Zealand university Hospital in Denmark. The sample size for the analysis contains more than 300 patients from different areas.
The samples of primary melanoma patients with progress have been compared with those patients whose primary melanoma did not show any progress. For analyzing the T cell range of tumors, Adaptive Biotechnologies performed high throughput DNA sequencing. It was found that out of all identified variables the T cell fraction (TCFr) was an independent and strong predictor for the patients’ progress condition.
Patients with the same lesion thickness were more at the risk of developing metastatic disease. If the TCFr value is lower than 20 % in the patients, then they are more at the risk of disease progression. On the other hand, if the TCFr value is more than 20% then the risk of disease progression is low in patients.
The test used in this study is not available at the commercial level for clinical use. It is only used for research purposes. The authors said that the study is retrospective because it took the sample and data of patients that are already available. While the prospective study is that in which data for outcomes is not known and further tests are needed for validation.
Kupper and colleagues imagine that if a test could bring to the clinics then it will improve the patient care and strengthen the results. The test is elegant, simple and quantitative. These types of tests will help us in the future to modify the treatments according to the situation. If the patients have high TCFr then we will benefit him with checkpoint inhibitor therapy. If the value is low in patients, then more interventions are needed.
- Cannabis1 year ago
How CBD oil works?
- Cannabis11 months ago
CBD Gummies: How does it work? Benefits, Pricing and Packages
- Health6 months ago
Diabetes Freedom Review – A Natural Way To Beat Diabetes Type 2
- Cannabis1 year ago
Research Suggests Cannabis Effective in Treating Endometriosis
- Featured9 months ago
Prosper Wellness TurmeriCBD Review – A combination of Turmeric and CBD?
- Cannabis11 months ago
What are the main advantages of consuming CBD oil?
- Health7 months ago
VitaMove, a Popular Formula to Relieve Back Pain is Restocked
- Cannabis8 months ago
Can Cannabis Survive in Pharma?